CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics today announced its debut as a stand-alone clinical-stage biotechnology company developing novel small molecule Tie-2 activators and HIF-1a stabilizers for multiple diseases. Aerpio was created in a spin-out transaction from Akebia Therapeutics and is seeking to raise a Series A financing round in 2012.
